1. Home
  2. MAR vs MRNA Comparison

MAR vs MRNA Comparison

Compare MAR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marriott International

MAR

Marriott International

N/A

Current Price

$414.78

Market Cap

110.5B

ML Signal

N/A

Logo Moderna Inc.

MRNA

Moderna Inc.

N/A

Current Price

$200.83

Market Cap

91.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAR
MRNA
Founded
1927
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.5B
91.2B
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
MAR
MRNA
Price
$414.78
$200.83
Analyst Decision
Buy
Hold
Analyst Count
29
23
Target Price
★ $421.73
$164.53
AVG Volume (30 Days)
1.4M
★ 11.4M
Earning Date
11-02-2026
11-06-2026
Dividend Yield
★ 0.69%
N/A
EPS Growth
14.17
★ 21.77
EPS
★ 8.36
N/A
Revenue
★ $26,186,000,000.00
$19,263,000,000.00
Revenue This Year
$6.81
$24.09
Revenue Next Year
$5.97
$11.33
P/E Ratio
$50.87
★ N/A
Revenue Growth
★ 4.33
4.29
52 Week Low
$282.03
$22.28
52 Week High
$433.30
$280.80

Technical Indicators

Market Signals
Indicator
MAR
MRNA
Relative Strength Index (RSI) 56.71 43.06
Support Level $362.04 $181.02
Resistance Level $432.62 $254.48
Average True Range (ATR) 10.53 17.92
MACD -1.75 -7.14
Stochastic Oscillator 34.24 11.39

Price Performance

Historical Comparison
MAR
MRNA

About MAR Marriott International

Marriott operates 1.8 million rooms across more than 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: